Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature

2.50
Hdl Handle:
http://hdl.handle.net/2336/13455
Title:
Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature
Authors:
Abildgaard, Lotte; Ellebaek, Eva; Gustafsson, Göran; Abrahamsson, Jonas; Hovi, Liisa; Jonmundsson, Gudmundur; Zeller, Bernward; Hasle, Henrik
Citation:
Ann. Hematol. 2006, 85(5):275-80
Issue Date:
1-May-2006
Abstract:
Children with Down syndrome (DS) and myeloid leukaemia have a significantly higher survival rate than other children, but they also experience considerable treatment-related toxicity. We analysed data on 56 children with DS who were treated on the Nordic Society for Paediatric Haematology and Oncology-acute myeloid leukaemia (NOPHO-AML)88 and NOPHO-AML93 protocols and reviewed the literature. In the dose-intensive NOPHO-AML88 protocol, 8 out of 15 patients (53%) experienced an event. In the less dose-intensive NOPHO-AML93 protocol, 7 out of 41 patients (17%) had an event. Therapy was reduced in 29 patients (52%) with in average 75% and 67% of the scheduled dose of anthracycline and cytarabine, respectively. Treatment-related death occurred in seven who all received full treatment. Relapse and resistant disease occurred at a similar rate in those receiving full and reduced treatment. Review of major series of myeloid leukaemia of DS showed no clear relationship between dose and survival; however, it appears that both a reduction in treatment dose and a less intensively timed treatment regimen improved the outcome. Further studies are needed to define the optimal regimen for treating myeloid leukaemia of DS.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://www.springerlink.com/content/w253617x47753801

Full metadata record

DC FieldValue Language
dc.contributor.authorAbildgaard, Lotte-
dc.contributor.authorEllebaek, Eva-
dc.contributor.authorGustafsson, Göran-
dc.contributor.authorAbrahamsson, Jonas-
dc.contributor.authorHovi, Liisa-
dc.contributor.authorJonmundsson, Gudmundur-
dc.contributor.authorZeller, Bernward-
dc.contributor.authorHasle, Henrik-
dc.date.accessioned2007-09-04T09:15:35Z-
dc.date.available2007-09-04T09:15:35Z-
dc.date.issued2006-05-01-
dc.date.submitted2007-09-04-
dc.identifier.citationAnn. Hematol. 2006, 85(5):275-80en
dc.identifier.issn0939-5555-
dc.identifier.pmid16518605-
dc.identifier.doi10.1007/s00277-005-0045-5-
dc.identifier.otherPED12-
dc.identifier.urihttp://hdl.handle.net/2336/13455-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractChildren with Down syndrome (DS) and myeloid leukaemia have a significantly higher survival rate than other children, but they also experience considerable treatment-related toxicity. We analysed data on 56 children with DS who were treated on the Nordic Society for Paediatric Haematology and Oncology-acute myeloid leukaemia (NOPHO-AML)88 and NOPHO-AML93 protocols and reviewed the literature. In the dose-intensive NOPHO-AML88 protocol, 8 out of 15 patients (53%) experienced an event. In the less dose-intensive NOPHO-AML93 protocol, 7 out of 41 patients (17%) had an event. Therapy was reduced in 29 patients (52%) with in average 75% and 67% of the scheduled dose of anthracycline and cytarabine, respectively. Treatment-related death occurred in seven who all received full treatment. Relapse and resistant disease occurred at a similar rate in those receiving full and reduced treatment. Review of major series of myeloid leukaemia of DS showed no clear relationship between dose and survival; however, it appears that both a reduction in treatment dose and a less intensively timed treatment regimen improved the outcome. Further studies are needed to define the optimal regimen for treating myeloid leukaemia of DS.en
dc.language.isoenen
dc.publisherSpringer Verlagen
dc.relation.urlhttp://www.springerlink.com/content/w253617x47753801en
dc.subject.meshAnthracyclinesen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocolsen
dc.subject.meshChild, Preschoolen
dc.subject.meshCytarabineen
dc.subject.meshDisease-Free Survivalen
dc.subject.meshDown Syndromeen
dc.subject.meshLeukemia, Myeloiden
dc.subject.meshSurvival Rateen
dc.titleOptimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literatureen
dc.typeArticleen
dc.identifier.journalAnnals of hematologyen
dc.format.digYES-

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.